Reticulocyte production index as a predictor of clinically significant anemia in chronic hepatitis C patients receiving pegylated interferon combination therapy  by Yan, Sheng-Lei et al.
Advances in Digestive Medicine (2016) 3, 18e23Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.aidm-onl ine.comORIGINAL ARTICLEReticulocyte production index as a predictor
of clinically significant anemia in chronic
hepatitis C patients receiving pegylated
interferon combination therapy
Sheng-Lei Yan a, Cheng-Shyong Chang b, Chien-Hua Chen a,c,*,
Yung-Hsiang Yeh a,c, Chien-Yu Tsai ba Division of Gastroenterology, Department of Internal Medicine, Chang Bing Show-Chwan Memorial
Hospital, Changhua County 505, Taiwan
b Division of Hemato-Oncology, Department of Internal Medicine, Changhua Christian Hospital,
Changhua, Taiwan
c Division of Gastroenterology, Department of Internal Medicine, Show-Chwan Memorial Hospital,
Changhua, TaiwanReceived 4 August 2014; accepted 23 October 2014
Available online 22 April 2015KEYWORDS
Anemia;
Hepatitis C;
Pegylated interferon;
Reticulocyte production* C
Sect
E
http:
2351
for t
creaindexorresponding author. Division of
ion 1, Chung-Shang Road, Changh
-mail address: yslendo@gmail.com
//dx.doi.org/10.1016/j.aidm.201
-9797/Copyright ª 2015, The Gas
he Study of the Liver. Published
tivecommons.org/licenses/by-nc-Summary Background: This work was conducted to study the relationship of reticulocyte
production index to clinically significant anemia in chronic hepatitis C patients receiving pegy-
lated interferon combination therapy.
Methods: A total of 69 chronic hepatitis C patients receiving pegylated interferon combination
therapy were included. Clinically significant anemia was defined as a hemoglobin level of <
10 g/dL. Reticulocyte count values were determined at the baseline and during treatment
(4 weeks, 12 weeks, and 24 weeks). Reticulocyte production indices were calculated according
to formulae. Clinical variables were analyzed using univariate analysis. Variables that were
found to be significant on univariate analysis were included in multivariate analysis. A p value
< 0.05 was regarded as statistically significant.
Results: Clinically significant anemia was observed in 30 patients (43.5%), and 39 patients
(56.5%) never developed clinically significant anemia during the whole treatment course. On
multivariate analysis, age > 60 years [odds ratio (OR), 2.94; 95% confidence interval (CI),
1.09e7.93], pretreatment hemoglobin level < 14 g/dL (OR, 5.76; 95% CI, 2.01e16.48), and
reticulocyte production index < 0.9% (OR, 5.50; 95% CI, 1.78e16.97) at Week 4 were signifi-
cantly associated with clinically significant anemia.Gastroenterology, Department of Internal Medicine, Show-Chwan Memorial Hospital, Number 542,
ua 500, Taiwan.
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Reticulocyte production index and anemia 19Conclusion: Besides old age and low pretreatment hemoglobin level, our study showed that a
reticulocyte production index < 0.9% at Week 4 was a significant factor associated with clin-
ically significant anemia during pegylated interferon combination treatment.
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Combination therapy with pegylated interferon (PegIFN)
and ribavirin can significantly improve sustained virological
response (SVR) rate and is recommended in the treatment
of patients with chronic hepatitis C [1,2]. However, pa-
tients receiving PegIFN combination therapy may develop
severe anemia, which might lead to dose reduction,
treatment discontinuation, and subsequent treatment
failure [3]. A number of mechanisms are involved in the
development of anemia, such as dose-dependent ribavirin-
induced hemolysis [4] and/or interferon-induced bone
marrow suppression [4,5]. Reticulocytes are red blood cells
that have been recently released from the bone marrow,
and a reticulocyte count is generally considered to be a
measure of red blood cell production. However, in order to
estimate the bone marrow response to anemia, the retic-
ulocyte count should be adjusted to yield a reticulocyte
production index (RPI) [6]. The aim of this study is to
examine whether RPI can predict clinically significant
anemia (CSA) in patients receiving PegIFN combination
therapy.
Materials and methods
Patients
This study was conducted in a prospective manner from May
2011 to May 2012. All patients were anti-hepatitis C virus
(HCV) antibody positive, had HCV RNA detectable in their
serum by the polymerase chain reaction method, and
showed elevated serum alanine transaminase (above the
upper limit of the normal), serum hemoglobin (Hb)
concentration > 12 g/dL, neutrophil > 1500/mm3, and
platelets > 105/mm3 within 6 months prior to the treat-
ment. Patients were excluded if they had baseline neu-
tropenia (neutrophil count < 1500/mm3),
thrombocytopenia (platelet count < 105/mm3), anemia (Hb
level < 12 g/dL in women and < 13 g/dL in men), human
immunodeficiency virus, hepatitis A or hepatitis B virus
coinfection, decompensated liver disease, a serum creati-
nine level > 1.5 times the upper limit of normal, poorly
controlled psychiatric disease, a recent alcohol or drug
dependence, or substantial coexisting medical conditions.
This study was approved by the Medical Ethics Committee
of Chang Bing Show-Chwan Memorial Hospital, Changhua,
Taiwan. Informed consent was obtained from each patient
included in the study, and the study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki.Treatment schedule
All patients were treated with PegIFN a-2a (PEGASYS;
Roche, Basel, Switzerland) 180 mg subcutaneously once
weekly or PegIFN a-2b (Pegintron; Schering-Plough,
Kenilworth, NJ, USA) 1.5 mg/kg body weight subcutane-
ously once weekly, both in combination with oral ribavirin
(Rebetol; Schering-Plough) at 1000e1200 mg/d dosed by
body weight (< 75 kg, 1000 mg/d; > 75 kg, 1200 mg/d) for
24 weeks or 48 weeks. Patients with undetected HCV RNA
at 4 weeks [rapid virological response (RVR)] received
combination therapy for 24 weeks, whereas those without
RVR received combination therapy for 48 weeks. Patients
with an insufficient viral response at 12 weeks (detected
HCV RNA with < 2elog10 decrease in HCV RNA from
baseline) were considered to have treatment failure and
discontinued therapy. Early virological response (EVR)
was defined as undetected HCV RNA at 12 weeks of
combination treatment. SVR was defined as undetected
HCV RNA at 24 weeks after combination treatment.
Ribavirin was given orally twice per day for the total dose.
PegIFN was discontinued if the absolute neutrophil count
was < 500/mm3 or the platelet count was < 5.0  104/
mm3. When the patients’ Hb dropped to < 10 g/dL,
erythropoietin (EPO) 5000 U was injected subcutaneously
per week. The patients were followed up at a 2-week
interval. The ribavirin dose of 200 mg was reduced when
the Hb concentration was still < 10 g/dL 2 weeks later.
Ribavirin was discontinued when the Hb concentration
decreased to < 8.5 g/dL, in accordance with the drug
information for ribavirin [7]. The patients were divided
into two groups: a CSA group and a non-CSA (without CSA)
group.Blood tests
All patients were examined for hematological and
biochemical tests just prior to therapy, at the end of Week
2, Week 4, and every 4 weeks during the combination
treatment. When the treatment was completed, the pa-
tients were assessed every 4 weeks up to 24 weeks after the
end of treatment. HCV RNA levels were measured
[screening visit (baseline); treatment Week 4, Week 12,
Week 24, and Week 48; and follow-up Week 24] using the
COBAS TaqMan assay (Roche Diagnostics, Indianapolis, IN,
USA), with a lower limit of quantitation at 27 IU/mL. Gen-
otyping of HCV was performed using a reverse hybridization
assay (Inno-LIPA HCV II; Innogenetics N.V., Zwijnaarde,
Belgium).
Table 1 Baseline characteristics of 69 enrolled patients.
Variables N (%) or mean  SD
Sex
Male 38 (55)
Female 31 (45)
Age (y) 55.8  11.9
Pretreatment ALT (U/L) 102.4  56.07
Pretreatment HCV RNA (log10 IU/mL) 6.1  0.92
Genotype
1 49 (71)
Non-1 20 (29)
PegIFN
a-2a 35 (51)
a-2b 34 (49)
WBC (/mL) 5622  1321
Pretreatment Hb (g/dL) 14.5  1.35
Pretreatment Hct (%) 42.4  3.64
Platelet (104/mL) 18.4  7.23
mean corpuscular volume (/fL) 92.8  5.44
Total bilirubin (mg/dL) 0.7  0.31
ALT Z alanine transaminase; Hct Z hematocrit;
HCV Z hepatitis C virus; PegIFN Z pegylated interferon;
SD Z standard deviation; WBC Z white blood cell count.
Table 2 Characteristics of patients with clinically signifi-
cant anemia (CSA) and without CSA (non-CSA).
Variables CSA Non-CSA p
Male 11 27 0.007
Female 19 12
Mean age (y) 60.9  8.61 51.9  12.7 0.001
WBC (/mL) 5400  1255 5814  1352 0.146
Pretreatment Hb (g/dL) 13.7  1.23 15.0  1.18 < 0.001
Platelet (104/mL) 17.8  7.55 18.8  7.04 0.573
Mean corpuscular
volume (/fL)
92.1  6.34 93.3  4.65 0.371
Total bilirubin (mg/dL) 0.7  0.274 0.8  0.334 0.486
Pretreatment HCV RNA
(log10 IU/mL)
5.8  0.993 6.3  0.783 0.012
PegIFN a-2b 12 23 0.118
PegIFN a-2a 18 16
Genotype 1 22 27 0.710
Nongenotype 1 8 12
RVR 7 15 0.181
Non-RVR 23 24
EVR 18 29 0.205
Non-EVR 12 10
SVR 15 27 0.105
Non-SVR 15 12
EVR Z early virological response; HCV Z hepatitis C virus;
PegIFN Z pegylated interferon; RVR Z rapid virological
response; SDZ standard deviation; SVRZ sustained virological
response; WBC Z white blood cell count.
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Hb and hematocrit (Hct) values at the baseline, during
treatment (4 weeks, 12 weeks, 24 weeks, 36 weeks, and 48
weeks), and 24 weeks after treatment were obtained for
calculation of RPI. Reticulocyte count values were deter-
mined at the baseline and during treatment (4 weeks, 12
weeks, and 24 weeks). CSA was defined as an Hb level <
10 g/dL [7]. The corrected reticulocyte count and RPI were
defined using the following formulae:
Corrected reticulocyte count Z Reticulocyte
count  (patient’s hematocrit/normal hematocrit)
Reticulocyte production index Z corrected reticulocyte
count  correction factor.
The correction factor was 1 for Hct of 36e45%, 1.5 for
Hct of 26e35%, 2 for Hct of 16e25%, and 2.5 for Hct < 15%
[6]. Because administration of EPO may influence the value
of reticulocyte count, only RPI values prior to EPO admin-
istration were used for statistical analysis in the CSA group.
Statistical analysis
Statistical analysis was performed using Minitab 14.1 (Min-
itab Incorporated, State College, PA, USA). Chi-square tests
(for categorical variables) or Student t tests (for continuous
variables) were used to make comparisons of these two
groups. Variables analyzed included age, sex, brands of
PegIFN, pretreatment Hb, pretreatment alanine trans-
aminase, pretreatment HCV RNA, genotype, RVR, EVR, SVR,
and RPIs at Week 0, Week 4, and Week 12. Paired t tests
were used to make pairwise comparisons of RPIs at
different time points of combination therapy within either
the CSA or the non-CSA group. Variables that were found to
be significant with p < 0.05 on univariate analysis were
included in the multivariate analysis. Stepwise logistic
regression analysis was performed to identify the inde-
pendent factors associated with CSA. Data were expressed
as mean  standard deviation. All tests were two-tailed,
and p < 0.05 was regarded as statistically significant.
Results
Patient characteristics
Between May 2011 and May 2012, a total of 69 patients with
chronic HCV (38 men, 31 women; mean age 55.8 years,
range 21e73 years) were included in the study and treated
with combination therapy. The baseline characteristics of
included patients are summarized in Table 1. Of the 69
included patients, 49 (71%) were genotype 1 and 20 (29%)
were nongenotype 1. Thirty-five patients received PegIFN
alpha-2a combination therapy, and 34 patients were
treated with PegIFN alpha-2b combination therapy. CSA was
observed in 30 patients (43.5%) (Table 2). Thirty-nine pa-
tients (56.5%) never had an Hb level < 10 g/dL during the
whole treatment course. Of the 30 patients in the CSA
group, five patients developed CSA at Week 4, 14 patientsdeveloped CSA between Week 4 and Week 12, and 11 pa-
tients developed CSA between Week 12 and Week 24.
Two out of 39 patients in the non-CSA group did not
complete the whole treatment course because of side
Table 3 Reticulocyte count (R) and reticulocyte production index (RPI) at baseline (R0, RPI0), Week 4 (R4, RPI4), and Week 12
(R12, RPI12) of patients with clinically significant anemia (CSA) and without CSA (non-CSA).
Variables (%) CSA Non-CSA p
R0 1.48  0.66 (n Z 30) 1.67  1.01 (n Z 39) 0.346
R4 1.74  0.79 (n Z 30) 2.01  1.67 (n Z 39) 0.392
R12 2.26  0.94 (n Z 11) 1.92  1.44 (n Z 39) 0.159
RPI0 1.33  0.633 (n Z 30) 1.61  0.929 (n Z 39) 0.148
RPI4 0.94  0.415 (n Z 30) 1.59  0.987 (n Z 39) 0.001
RPI12 0.98  0.419 (n Z 11) 1.39  0.849 (n Z 39) 0.034
Figure 1 (A) Mean values of reticulocyte count and at
baseline (W0) and Week 4 (W4) of patients with clinically sig-
nificant anemia (n Z 30) are demonstrated without significant
difference. (B) Mean values of reticulocyte production index
(RPI) at baseline (W0) and Week 4 (W4) of patients with clini-
cally significant anemia (n Z 30) are demonstrated. * Signifi-
cant difference as compared with RPI at baseline.
Reticulocyte production index and anemia 21effects and discontinued therapy at Week 28 and Week 35,
respectively. Four out of 30 patients in the CSA group did
not complete the whole treatment course. Three patients
discontinued treatment at Week 14, Week 15, and Week 18,
respectively, owing to intolerance of anemic symptoms. A
fourth patient discontinued treatment at Week 39 because
of a traffic accident.
Predictors of CSA
Table 2 demonstrates the characteristics of patients with
CSA and those without CSA. On univariate analysis, women
were prone to develop CSA (c2 Z 7.267, p Z 0.007). The
mean age in the CSA group was 60.9 years, which was
significantly higher than that in the non-CSA group
(pZ 0.001). The mean level of pretreatment Hb in the CSA
group was 13.7 g/dL, which was significantly lower than
that in the non-CSA group (p Z 0.001). The pretreatment
values of white blood cell count, platelet, mean corpus-
cular volume, and total bilirubin showed no significant
differences between both groups (p > 0.05, Table 2). The
pretreatment level of HCV RNA in the CSA group was 5.8
log10 IU/mL, which was significantly lower than 6.3
log10 IU/mL in the non-CSA group (p Z 0.012). Other pa-
rameters such as PegIFN alpha-2a or alpha-2b, genotype,
RVR, EVR, and SVR revealed no significant differences be-
tween both groups (p > 0.05, Table 2).
Because all patients in the CSA group developed CSA no
later than Week 24, only values of reticulocyte count and
RPI at baseline, Week 4, and Week 12 were adopted for
statistical analysis. Table 3 demonstrates the values of
reticulocyte count and RPI between both groups at base-
line, Week 4, and Week 12. The values of reticulocyte count
in the CSA group at baseline, Week 4, and Week 12 were not
significantly different from those in the non-CSA group
(p > 0.05). The RPI at Week 0 of the CSA group was 1.33%,
which was not significantly different from that of the non-
CSA group (p > 0.05). However, the RPI at Week 4 of the
CSA group was 0.94%, which was significantly lower than
that of the non-CSA group (p < 0.05) Furthermore, the RPI
at Week 12 of the CSA group was 0.98%, which was also
significantly lower than that of the non-CSA group
(p < 0.05). Out of the 30 patients in the CSA group, five
patients developed CSA at Week 4, 14 patients developed
CSA between Week 4 and Week 12, and 11 patients devel-
oped CSA between Week 12 and Week 24. There were no
significant differences in RPI among these three subgroups
(p > 0.05). A pairwise comparison of reticulocyte counts at
baseline and Week 4 of 30 patients in the CSA grouprevealed no significant differences (p > 0.05, Fig. 1A).
However, a pairwise comparison of RPI values at baseline
and Week 4 in the CSA group showed a significant difference
(p Z 0.007, Fig. 1B). On the contrary, a pairwise compar-
ison of reticulocyte counts (and RPIs) at baseline, Week 4,
and Week 12 in the non-CSA group revealed no significant
differences (p > 0.05, Fig. 2).
Variables that were significant with p< 0.05 on univariate
analysis were sex, age, pretreatment Hb, pretreatment HCV
RNA, and RPI at Week 4 and Week 12 (Tables 2 and 3).
Although RPI at Week 12 was significantly associated with
CSA, only RPI at Week 4 was included in the multivariate
Figure 2 (A) Mean values of reticulocyte count at baseline
(W0), Week 4 (W4), and Week 12 (W12) of patients without
clinically significant anemia (nZ 39) are demonstrated. There
are no significant differences among the three groups. (B) Mean
values of reticulocyte production index (RPI) at baseline (W0),
Week 4 (W4), and Week 12 (W12) of patients without clinically
significant anemia (n Z 39) are demonstrated. There are no
significant differences among the three groups.
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anemia. In order to identify the independent factors asso-
ciated with CSA, a stepwise logistic regression analysis was
performed. As shown in Table 4, age of  60 years
(pZ 0.031), pretreatment Hb level of< 14 g/dL (pZ 0.001),Table 4 Significant factors associated with clinically significant
Variables Univari
CSA (n Z 30) No
Mean age (y)
 60/< 60
17/13 12/
Pretreatment Hb (g/dL)
 14/> 14
19/11 9/3
RPI4 (%)
 0.9/> 0.9
15/15 6/3
Pretreatment HCV RNA (log10 IU/mL)
 6.0/> 6.0
16/14 11/
Sex: male/female 11/19 27/
CI Z confidence interval; CSA Z clinically significant anemia; Hb Z
OR Z odds ratio; RPI4 Z reticulocyte production index at Week 4.and RPI of < 0.9 % at Week 4 (pZ 0.002) were significantly
associated with CSA by univariate analysis. The stepwise
logistic regression analysis showed that the odds ratios (ORs)
were 2.94 [95% confidence interval (CI), 1.09e7.93] for pa-
tient age of  60 years, 5.76 (95% CI, 2.01e16.48) for pre-
treatment Hb level of < 14 g/dL, and 5.50 (95% CI,
1.78e16.97) for RPI of < 0.9% at Week 4 (Table 4).Discussion
Chronic HCV patients receiving PegIFN combination therapy
may develop moderate to severe anemia, with mean HB
decreases of 2.5 g/dL and 3.7 g/dL in clinical trials of
PegIFN alfa-2b [1] and PegIFN alfa-2a [2], respectively.
Several clinical factors have been reported to be predictive
of anemia during antiviral therapy, such as age, female sex,
pretreatment platelet count, and pretreatment Hb level
[8e11]. Furthermore, an Hb drop of > 1.5 g/dL [12] or >
2 g/dL [13e15] at Week 2 of combination therapy was re-
ported to be useful in early prediction of severe anemia.
However, in a recent study by Hu et al [16], older age, high
baseline Hb concentration, high HCV RNA level, and low
estimated glomerular infiltration rate and low platelet
count were independent predictors of significant decline of
Hb levels. In the current study, several factors were found
to be significantly different between the CSA and non-CSA
groups. Patient age of  60 years (OR Z 2.94,
p Z 0.033), pretreatment Hb level of < 14 g/dL
(OR Z 5.76, p Z 0.001), and RPI of < 0.9% at Week 4
(OR Z 5.50, p Z 0.003) were independent significant fac-
tors for CSA during combination treatment. Our study
demonstrated that RPI at Week 4 can be regarded as a
reliable factor associated with CSA during combination
therapy.
Reticulocytes are immature red blood cells that have
been recently released from the bone marrow. Reticulocyte
count should be adjusted to yield an RPI to provide an es-
timate of erythropoiesis efficiency and productivity of bone
marrow [6]. If the RPI is < 2% in the face of established
anemia, a defect in erythroid marrow proliferation or
maturation must be present [6]. In the current study, those
who developed CSA during PegIFN combination therapy had
a significantly lower RPI at Week 4, as compared with thoseanemia (CSA) by univariate and multivariate analysis.
ate analysis Multivariate analysis
n-CSA (n Z 39) p OR (95% CI) p
27 0.031 2.94 (1.09e7.93) 0.033
0 0.001 5.76 (2.01e16.48) 0.001
3 0.002 5.50 (1.78e16.97) 0.003
28 0.034 d d
12 0.007 d d
hemoglobin; HCV Z hepatitis C virus; non-CSA Z without CSA;
Reticulocyte production index and anemia 23who did not develop CSA. A significantly lower RPI at Week
12 was also noted in those who developed CSA at later than
Week 12, as compared with those who did not develop CSA.
Furthermore, when comparing the values of RPI at baseline
and Week 4, a significant difference existed in patients who
developed CSA. Those patients who never developed CSA
did not show a significant difference between values of RPI
at baseline and Week 4. Furthermore, it is worth noting
that values of RPI over time in patients with CSA were all <
2% (Table 3), which is suggestive of insufficient erythroid
marrow proliferation in the face of anemia [6]. These
findings suggested that those who experienced CSA during
PegIFN combination therapy had a significantly lower
erythroid marrow response to treatment-related anemia.
Based on this novel finding, we hypothesize that the bone
marrow suppression effect of PegIFN might play a pre-
dominant role in contributing to anemia in patients with
CSA. Moreover, the finding of insufficient erythroid marrow
response in the CSA group might support the observation of
a previous study. In an observational study conducted by
Balan et al [17], all subgroups of HCV-infected patients
receiving PegIFN combination therapy had diminished
endogenous EPO response. The authors concluded that
treatment-induced anemia of PegIFN combination therapy
may be attributable to suboptimal erythropoietic response
and bone marrow suppression [17].
The current study has several limitations. First, RPI at
Week 4 was found to be a significant predictor in this study.
However, more time points may be needed to elucidate the
best time point of using RPI in predicting CSA during com-
bination treatment. Second, development of anemia in
patients receiving PegIFN combination therapy is generally
considered to be a “mixed” effect of ribavirin-induced
hemolysis [4] and/or interferon-induced bone marrow
suppression [4,5]. In the current study, markers of hemo-
lysis, such as haptoglobin and lactate dehydrogenase were
not checked. Although a significant effect of bone marrow
suppression was observed during PegIFN combination ther-
apy, the effect of ribavirin-induced hemolysis in the course
of treatment remained unknown. Further prospective
studies may be needed to elucidate the distinct roles of
PegIFN and ribavirin in the development of treatment-
related anemia.
In conclusion, our study showed that patient age of 60
years or more, pretreatment Hb level of < 14 g/dL, and RPI
of < 0.9% at Week 4 were independent significant factors
associated with CSA during PegIFN combination treatment.
Patients who experienced CSA during PegIFN combination
therapy had an insufficient erythroid marrow response to
treatment-related anemia. The bone marrow suppression
effect of PegIFN might play an important role in contrib-
uting to treatment-related anemia in patients with CSA.
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